antibody in the sample indicates that the sample is positive for the presence of EGFR and a cleaving agent that cleaves the substrate in the cleavable moiety (CM) of the activatable antibody; (iii) means for identifying and selecting one or more subjects that test positive for the presence of EGFR and the cleaving agent thereby identifying or refining a patient population; and (iv) instructions for administering a therapeutically effective amount of an activatable antibody according to any one of claims 1 to 40 to the one or more subjects in the patient population that test positive for the presence of EGFR and the cleaving agent.

64. The kit of claim 63, wherein the anti-EGFR activatable antibody comprises a detectable label.

65. The kit of claim 64, wherein the detectable label comprises an imaging agent, a contrasting agent, an enzyme, a fluorescent label, a chromophore, a dye, one or more metal ions, or a ligand-based label.

66. The kit of claim 63, wherein the EGFR-related disorder is cancer.

67. The kit of claim 66, wherein the cancer is breast cancer, colorectal cancer, gastric cancer, glioblastoma, head and neck cancer, lung cancer, ovarian cancer, endometrial cancer, pancreatic cancer, prostate cancer, renal cancer, sarcoma, or skin cancer.

68. The kit of claim 63, wherein the EGFR-related disorder is an inflammatory disorder and/or an autoimmune disease, and optionally wherein the EGFR-related disorder is psoriasis.

69. Use of the activatable antibody of any one of claims 1 to 40 in the manufacture of a medicament for treating or delaying the progression of a disorder associated with aberrant expression and/or activity of EGFR in a subject.

70. The method of claim 60, wherein the EGFR-related disorder is a disorder associated with aberrant expression and/or activity of EGFR in a subject.

71. The kit of claim 63, wherein the EGFR-related disorder is a disorder associated with aberrant expression and/or activity of EGFR in a subject.

antibody in the sample indicates that the sample is positive for the presence of EGFR and a cleaving agent that cleaves the substrate in the cleavable moiety (CM) of the activatable antibody; (iii) means for identifying and selecting one or more subjects that test positive for the presence of EGFR and the cleaving agent thereby identifying or refining a patient population; and (iv) instructions for administering a therapeutically effective amount of an activatable antibody according to any one of claims 1 to 40 to the one or more subjects in the patient population that test positive for the presence of EGFR and the cleaving agent.

64. The kit of claim 63, wherein the anti-EGFR activatable antibody comprises a detectable label.

65. The kit of claim 64, wherein the detectable label comprises an imaging agent, a contrasting agent, an enzyme, a fluorescent label, a chromophore, a dye, one or more metal ions, or a ligand-based label.

66. The kit of claim 63, wherein the EGFR-related disorder is cancer.

67. The kit of claim 66, wherein the cancer is breast cancer, colorectal cancer, gastric cancer, glioblastoma, head and neck cancer, lung cancer, ovarian cancer, endometrial cancer, pancreatic cancer, prostate cancer, renal cancer, sarcoma, or skin cancer.

68. The kit of claim 63, wherein the EGFR-related disorder is an inflammatory disorder and/or an autoimmune disease, and optionally wherein the EGFR-related disorder is psoriasis.